Several randomized controlled trials have shown that adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular carcinoma (HCC). | Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma A propensity score-matched analysis of real-world data